Novartis Q4 Results

↓ ↑ Content Click below to navigate through the document ianalumab - BAFF-R inhibitor Company overview Financial review Conclusions NCT05648968 VAYHIA (CVAY736012301) Warm autoimmune hemolytic anemia Phase 3 Indication Phase Patients 90 Binary variable indicating whether a patient achieves a durable response Durable response: hemoglobin level ≥10 g/dL and ≥2 g/dL increase from baseline, for a period of at least eight consecutive weeks between W9 and W25, in the absence of rescue medication or prohibited treatment Arm 1: experimental lanalumab low dose (intravenously) Arm 2: experimental lanalumab high dose (intravenously) Arm 3: placebo Comparator (intravenously) Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Cardiovascular, Renal and Metabolic Immunology Neuroscience > Oncology Other Global Health Abbreviations Primary Outcome Measures Arms Intervention Readout Milestone(s) 2026 Publication TBD Target Patients Previously treated patients with warm Autoimmune Hemolytic Anemia References □ NOVARTIS Reimagining Medicine Novartis Q4 Results | January 31, 2024 71

View entire presentation